Performance of ATA Risk Stratification Systems, Response to Therapy, and Outcome in an Indian Cohort of Differentiated Thyroid Carcinoma Patients: A Retrospective Study

被引:12
作者
Ruben, Rony [1 ]
Pavithran, Praveen, V [1 ]
Menon, V. Usha [1 ]
Nair, Vasantha [1 ]
Kumar, Harish [1 ]
机构
[1] Amrita Inst Med Sci, Dept Endocrinol, Ponekkara PO, Kochi 682041, Kerala, India
关键词
ATA risk stratification systems; Differentiated thyroid carcinoma; Indian population; Kerala; Outcome; Validation; CANCER; RECURRENCE; ASSOCIATION; PERSISTENCE; RADIOIODINE; ABLATION;
D O I
10.1159/000500773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: For better individualized management of differentiated thyroid carcinoma (DTC), ATA risk stratification systems (RSS) of 2009 and 2015 as well as a response to therapy re-classification (ATA RTR-2015) are used worldwide for assessing risk of recurrence. But there are no validation studies of these systems from the Indian subcontinent. Objectives: To compare ATA RSS-2009, ATA RSS-2015, and ATA RTR-2015 for their accuracy in predicting outcome in DTC patients. Methods: This was a retrospective review of 236 adult patients with DTC >1 cm attending the Thyroid Cancer Clinic at our Institute who had undergone total thyroidectomy and radioactive iodine ablation. Initial risk stratification using ATA RSS-2009 and RSS-2015, clinical response at 1 year and outcome at last follow-up measured by clinical end points were collected and analyzed. Results: ATA RSS-2015 could not be applied to this cohort due to lack of histopathology details. While 77.3% of low-risk ATA RSS-2009 had disease-free status (NED, no evidence of disease) on follow-up, 96.1% of patients, in excellent response in ATA RTR-2015, showed NED. Whereas persistent structural disease was predicted by the high-risk group in ATA RSS-2009 (61.9%) and by the incomplete structural response group in ATA RTR-2015 (57.1%) equally well, the best predictor for NED at 1 year in this cohort was ATA RTR-2015 (p < 0.001). Conclusion: This study found that both ATA RSS-2009 and ATA RTR-2015 are reliable in predicting outcome in DTC patients after initial treatment. However, the response to initial therapy at 1 year predicted outcome more accurately than the initial risk status.
引用
收藏
页码:312 / 318
页数:7
相关论文
共 13 条
[1]   The Clinical and Economic Burden of a Sustained Increase in Thyroid Cancer Incidence [J].
Aschebrook-Kilfoy, Briseis ;
Schechter, Rebecca B. ;
Shih, Ya-Chen Tina ;
Kaplan, Edwin L. ;
Chiu, Brian C. -H. ;
Angelos, Peter ;
Grogan, Raymon H. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2013, 22 (07) :1252-1259
[2]   Clinical Risk Factors Associated with Cervical Lymph Node Recurrence in Papillary Thyroid Carcinoma [J].
Baek, Seung-Kuk ;
Jung, Kwang-Yoon ;
Kang, Sun-Mook ;
Kwon, Soon-Young ;
Woo, Jeong-Soo ;
Cho, Seung-Hyun ;
Chung, Eun-Jae .
THYROID, 2010, 20 (02) :147-152
[3]   Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients [J].
Castagna, Maria Grazia ;
Maino, Fabio ;
Cipri, Claudia ;
Belardini, Valentina ;
Theodoropoulou, Alexandra ;
Cevenini, Gabriele ;
Pacini, Furio .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (03) :441-446
[4]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[5]   Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study [J].
de Castro, Taciana Padilha ;
Waissmann, William ;
Simoes, Taynana Cesar ;
de Mello, Rossana Corbo R. ;
Carvalho, Denise P. .
CLINICAL ENDOCRINOLOGY, 2016, 85 (03) :466-474
[6]  
Haugen BR, 2015, THYROID, V2016, P261
[7]   Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review [J].
Leung A.M. ;
Dave S. ;
Lee S.L. ;
Campion F.X. ;
Garber J.R. ;
Pearce E.N. .
Thyroid Research, 4 (1)
[8]   Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems [J].
Pitoia, Fabian ;
Bueno, Fernanda ;
Urciuoli, Carolina ;
Abelleira, Erika ;
Cross, Graciela ;
Tuttle, R. Michael .
THYROID, 2013, 23 (11) :1401-1407
[9]   Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation [J].
Shen, Feng-Chih ;
Hsieh, Ching-Jung ;
Huang, I-Chin ;
Chang, Yen-Hsiang ;
Wang, Pei-Wen .
THYROID, 2017, 27 (04) :531-536
[10]   Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer [J].
Singer, PA ;
Cooper, DS ;
Daniels, GH ;
Ladenson, PW ;
Greenspan, FS ;
Levy, EG ;
Braverman, LE ;
Clark, OH ;
McDougall, IR ;
Ain, KV ;
Dorfman, SG .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (19) :2165-2172